Profile
Christopher Folk worked as the Director of Engineering & Device Manufacturing at ViaCyte, Inc. from 2016 to 2019.
He also worked as the Vice President of Engineering at Ra Medical Systems, Inc. In terms of education, he received an undergraduate degree from the University of Notre Dame, a graduate degree from the University of Cincinnati, and a doctorate from the University of California Los Angeles Graduate School.
Former positions of Christopher Folk
| Companies | Position | End |
|---|---|---|
ViaCyte, Inc.
 ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 2019-11-30 |
| CATHETER PRECISION, INC. | Chief Tech/Sci/R&D Officer | - |
Training of Christopher Folk
| University of Notre Dame | Undergraduate Degree |
| University of Cincinnati (Ohio) | Graduate Degree |
| University of California Los Angeles Graduate School | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Ra Medical Systems, Inc.
 Ra Medical Systems, Inc. Medical SpecialtiesHealth Technology Ra Medical Systems, Inc. engages in the design, development and commercialization of excimer lasers for the treatment of vascular immune-mediated inflammatory diseases. Its product, the Destruction of Arteriosclerotic Blockages by laser Radiation Ablation (DABRA) laser and single-use catheter, together referred to as DABRA, is used as a tool in the treatment of peripheral artery disease which commonly occurs in the legs. The company was founded by Dean Irwin and Melissa Burstein on September 4, 2002 and is headquartered in Fort Mill, SC. | Health Technology |
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Christopher Folk
